Found 15 matching trials
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer NA The investigators propose to conduct a single-center, single-arm, Phase I c...
Show More Status
Active Not Recruiting
Location
Colorectal Cancer, West China Hospital
Learn More & Join Trial
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer N/A The survival of the refractory CRC is dismal and therapy options are limite...
Show More Location
Hunan Cancer Hospital
Learn More & Join Trial
Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer PHASE1 This study is a multicenter, dose-escalating phase Ib clinical study to eva...
Show More Location
Harbin Medical University Cancer Hospital
Learn More & Join Trial
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer PHASE2 This study is a single-arm, open-label, single-center clinical trial design...
Show More Location
The First Hospital of Jilin University
Learn More & Join Trial
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma PHASE2 The purpose of this study is to evaluate the efficacy and safety of fruquin...
Show More Location
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Learn More & Join Trial
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer PHASE2 Colorectal cancer is a malignant tumor ranking among the top four in incide...
Show More Location
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999
Learn More & Join Trial
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors PHASE1 This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose ...
Show More Location
Honor Health Research Institute
Learn More & Join Trial
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC PHASE2 This is a multicenter, randomized, controlled, phase II study to evaluate t...
Show More Location
Shanghai Zhongshan Hospital
Learn More & Join Trial
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. PHASE2 The purpose of this study is to evaluate the efficacy and safety of fruquin...
Show More Location
Cancer Hospital of China Medical University/Liaoning Cancer Hospital &Institute
Learn More & Join Trial
Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma N/A To explore the efficacy and safety of fruquintinib and albumin-paclitaxel c...
Show More Location
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Learn More & Join Trial